New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Alaric DeArment
Reporter
Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.
Latest From Alaric DeArment
Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
Sarepta Charges Ahead With DMD Gene Therapy Despite Setback
The company plans to start its Phase III trial of SRP-9001 in the middle of this year, with a potential readout by the end of 2022.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
GSK Antibody Appears Effective In Older COVID-19 Patients
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.